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A dendritic poly(2-alkyloxazoline) based polymer was studied as a new carrier system for the 
organophosphorus-hydrolyzing recombinant enzymes, organophosphorus acid anhydrolase 
and organophosphorus hydrolase. Paraoxon and diisopropylfluorophosphate were used as 
model organophosphorus compounds. Changes in plasma cholinesterase activity were 
monitored. The cholinesterase activity was proportional to the concentrations of DFP or 
paraoxon. Plasma cholinesterase activity was higher in animals receiving enzyme and oxime 
before the organophosphates than in the oxime-only pre-treated groups.  These studies 
suggest that cholinesterase activity can serve as an indicator for the in vivo protection by the 
nano-intercalated organophosphorus acid anhydrolase or organophosphorus hydrolase against 
organophosphorus intoxications. These studies represent a practical application of polymeric 
nano-delivery systems as enzyme carriers in drug antidotal therapy.  
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The toxic effects of organophosphorus (OP) compounds are largely attributable to the 
inhibition of the enzyme acetylcholinesterase (AChE, EC. 3.1.1.7). AChE mediates the 
degradation of acetylcholine (ACh), a neurotransmitter of both the peripheral and the central 
nervous system.  When an electrical impulse reaches the presynaptic neuron, ACh is released 
and subsequently binds to a receptor (muscarinic or nicotinic). After binding, ACh is 
degraded by AChE, thus regenerating the receptor and rendering it active again. OP 
compounds inhibit AChE by phosphorylation (organophosponates by phosphonylation) of a 
serine hydroxyl located in the active site. Thus, ACh is not hydrolyzed and continues to 
interact with the receptor, resulting in persistent and uncontrolled stimulation. Clinical 
effects of OP compounds, which include common pesticides and nerve agents, are the result 
of this persistent stimulation and subsequent fatigue at the ACh receptor. The inactivation of 
AChE eventually becomes irreversible, a phenomenon known as aging. Once aging occurs, 
the AChE enzyme cannot be reactivated. For the clinical effect to be reversed, new enzyme 
has to be produced.  
Currently, the standard treatment for OP poisoning is the co-administration of the AChE 
reactivator pralidoxime (2-PAM) and the anticholinergic atropine (Tong et al., 1962).  
Atropine antagonizes the pharmacologic effects of acetylcholine by occupying the muscarinic 
receptors, thus blocking the effect of the accumulated acetylcholine. 2-PAM reactivates the 
inhibited AChE by nucleophilic displacement of the phosphate moiety. Although 2-PAM + 
atropine combination therapy can effectively treat the symptoms of OP poisoning, this is 
accomplished without protecting AChE from subsequent inhibition by the OP persistent in 
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the body.  If health effects of chemical agent exposure are to be minimized, a treatment 
should be developed to reduce or eliminate the OPs from the body, thus protecting AChE 
from inhibition.  
The ability of enzymes to detoxify OPs has long been recognized. Enzymes capable of 
detoxifying OPs include organophosphorus acid anhydrolase (OPAA) and organophosphorus 
hydrolase (OPH). OPAA is a recombinant OP hydrolyzing enzyme (Aldridge  et al., 1989) 
which demonstrates substrate specificity for the P-F bond of sarin, soman, and 
diisopropylfluorophosphate (DFP) (Cheng et al., 1993), while OPH has a broader substrate 
specificity and is capable of hydrolyzing P-O (paraoxon), P-F (DFP, soman and sarin), P-S 
(demeton-S and VX) and P-CN (tabun) bonds. The application of these enzymes for 
protection against OP poisoning is a concept with exciting potential in the treatment of both 
pesticide and chemical warfare agent (CWA) exposure.  
One of the earliest studies demonstrating the utility of enzymatic prophylaxis used resealed 
and annealed red blood cells (RBC) prepared by hypotonic dialysis as a carrier platform 
(DeLoach et al., 1980; Ihler et al., 1973).  Subsequently, carrier red blood cells (CRBC) were 
evaluated as enzyme carriers, originally in cyanide antagonism (Cannon et al., 1992; Leung 
et al., 1986; Petrikovics et al., 1995; Way et al., 1985), and more recently in OP antagonism 
(Pei et al., 1994, 1995). In addition to the CRBC, these enzymes have been deployed with 
other enzyme delivery platforms, including sterically stabilized liposomes (SL) (Allen 1994; 
Lasic and Papahadjopoulos, 1998; Szoka and Papahadjopoulos, 1980; Woodle and Lasic, 
1992). Encapsulation of OPAA and OPH within sterically stabilized liposomes (SL-OPAA 
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and SL-OPH, respectively) and the successful prophylactic/therapeutic application in OP 
antagonism has been reported (Petrikovics et al., 1999, 2000a, 2000b, 2004).  
Dendritic polymers (DP) have become a focus of research interest in the area of drug delivery 
systems (Dagani, 1996; Tomalia et al., 1985, 1986, 1997; Petrikovics et al., 2007, 2010; Yin 
et al., 1998).  Their general chemical structure is -(CH2CH2NR)-, where R is H, methyl, 
ethyl, or other alkyl groups. Recently, a novel hyper-branched polymer (HBP) with a CH3-
(CH2)17 surface-modified hyperbranched poly(2-ethyloxazoline) polymer was synthesized 
(Yin  et al., 1997). With the internal tertiary amide functional group on repeating 
ethyloxazoline units and external C18 chains, this HBP possesses a hydrophilic core and a 
hydrophobic shell. Dendritic polymers, including dendrimers, dendrigraft, and hyperbranched 
polymers, exhibit very different properties than the traditional linear polymers.  DPs are three 
dimensional, tree-like, spherical macromolecules whose size and shape resemble traditional 
micelles. However, unlike traditional lipid-based micelles, which tend to exist in equilibrium 
between self-assembled and randomly distributed lipids, the dendritic polyoxazoline 
polymeric micelles can withstand a variety of environmental conditions, including solvent, 
temperature and pH extremes. These DPs have been used to encapsulate OPH (DP-OPH) and 
OPAA (DP-OPAA) in the presence of a surface decontaminant (EcoTru, Enviro Systems, 
Inc., San Jose, CA) and tested as potential catalyst-based dual-use CWA decontamination 
 formulation (Chen et al., 2004; Petrikovics et al., 2007). 
This study describes the in vitro efficacy of OPAA and OPH, when encapsulated within a 
dendritic poly(2-alkyloxazoline) polymer based nanocapsules, in decreasing AChE inhibition 
by DFP and paraoxon, respectively. Since OP compounds are cholinesterase inhibitors, 
 6
monitoring the AChE level in biologic fluids is utilized as an indicator of the efficacy of the 
different OP antidotal systems.   
    
Material and Methods 
Chemicals 
Paraoxon and DFP were purchased either from Sigma-Aldrich (St. Louis, MO). When 
necessary, paraoxon was further purified by aqueous sodium bicarbonate extraction (Pei et 
al., 1994). Atropine sulfate and 2-PAM solutions were prepared fresh daily. OPAA was a 
generous gift from the laboratory of T.C. Cheng (US Army Edgewood Chemical & 
Biological Center, Aberdeen Proving Ground, MD 21010-5423, USA) and stored at –70 ºC 
in 1 µM DTT (Cheng et al., 1993; DeFrank et al., 1991). Recombinant OPH (E.C. 3.1.8.1) 
was purified from Escherichia coli DH5α containing the plasmid expression vector pOP419, 
and purified as previously reported (Lai et al., 1994).  AChE was purchased from Sigma-
Aldrich (930 Units/ml).  
 
Animals  
Male Balb/C mice (Charles River Breeding Laboratories, Inc., Wilmington, MA) weighing 
between 18-20 g were housed in room temperature and light controlled rooms, (21 ± 2 oC, 
12-h light/dark cycle) and were furnished with water and 4% fat Rodent Chow (Teklad HSD, 
Inc., WI) ad libitum. All animal procedures were conducted in accordance with the 
guidelines in The Guide for the Care and Use of Laboratory Animals (National Academic 
Press, 1996), credited by AAALAC (American Association for the Assessment and 
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Accreditation of Laboratory Animal Care, International). At the termination of the 
experiments, surviving animals were euthanized with “Aerrane” (Isoflurane) from Fort 
Dodge Animal Heath, (Forth Dodge, IA) in accordance with the 1986 report of the AVMA 
Panel of Euthanasia. 
 
Determination of enzymatic activity (OPAA and OPH) 
OPAA activity was measured by monitoring the production of fluoride from DFP with a 
fluoride ion sensitive electrode (Orion Research Inc., Boston, MA) (Hoskin & Roush 1982). 
The assay solution for the enzyme fractions contained 70 mM Tris, pH 7.2, with 70 mM 
NaCl, 280 mM KCl, and 3.44 mM DFP. The solution for determining the activity of DP 
encapsulated enzyme was isotonic (290 mOsm), and composed of 10 mM phosphate buffer, 
144 mM NaCl, 2.0 mM MgCl2*6H2O and 5 mM dextrose. The total volume of the reaction 
mixture was 5 ml. The electrode potential was recorded as a function of time and potential 
values were converted to concentration using the Nernst equation. Protein assays were 
accomplished by the Bradford method (Bradford, 1976) using BioRad protein assay reagents 
(BioRad, Richmond, CA). One unit of OPAA is defined as the amount of enzyme which 
hydrolyzed one µmol of DFP to fluoride and isopropyl phosphate per min.  
OPH activity was measured at room temperature spectrophotometrically, following the rate 
of formation of p-nitrophenol (p-NP) from paraoxon. The standard solution used to 
determine OPH activity was isotonic (290 mOsm) containing 15 mM phosphate buffer (pH 
7.8), 216 mM NaCl, 0.08 mM ZnCl2, 3.0 mM MgCl2, and varying amounts of DP-OPH in a 
final volume of 2.0 ml. The reaction was initiated with the addition of DP-OPH, and 
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monitored at 400 nm. One unit of OPH is defined as that amount of enzyme which 
hydrolyzes one µmol of paraoxon per min. Protein assays were performed by the Bradford 
method (Bradford, 1976) using the Bio-Rad protein assay reagent (Bio-Rad, Richmond, CA). 
 
Preparation of nano-intercalated OPAA and OPH 
The synthetic work was performed as reported by Yin et al. (1997). The hyper-branched 
poly(2-ethyloxazoline) with CH5(CH2)17 chain modified surface was synthesized by a 
convergent method and is referred to as C18-HBP20/100, where the subscript 20/100 represents 
the average number of repeat units for interior branches and the center core molecule (i.e., 20 
and 100 repeat units, respectively).  
The DP was dissolved in Bis-Tris-Propane buffer (BTP) (50 mM, pH 8.5) and then combined 
with the BTP solution of OPAA or OPH to make up the final solution of 20 mg dendrimer-
enzyme mixture per ml. Various ratios of polymer to enzyme (w/w) were evaluated, and the 
ratios of 10:1 and 20:1 worked optimally for the OPAA and OPH enzyme encapsulation, 
respectively. The DP carrier systems encapsulating the OPAA or OPH were then lyophilized, 
giving a powder of DP-OPAA or DP-OPH with the enzyme activity of 1-5 units/mg. For in 
vivo studies they were dissolved in sterile water to provide the required enzyme units (100 
units of OPAA, 20 units of OPH) for each test animal. In lyophilized form, the encapsulated 
OPAA or OPH are stable for months (Cheng et al., 2004).  
 
In vitro AChE inhibition by OP’s 
AChE was re-suspended to 1 mg/ml in 100 mM phosphate buffer, pH 7.4 and allowed to 
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hydrate for 24 hours.  Inhibition levels were established for each OP by incubating 0.1 mg/ml 
AChE for 24 hours with a series of OP concentrations. After incubation the enzyme was 
further diluted to 0.033 mg/ml.  Acetylthiocholine (ASCh, 1 mM) was used as the substrate 
and the reaction was monitored spectrophotometrically at 405 nm for the reaction product 
using 1 mM 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB).  The amount of OP used in the 
protection studies corresponded to the level that inhibited the enzyme to >95%; the absolute 
concentration varied by lot of AChE.  
  
In vivo plasma cholinesterase studies  
Male mice received 100 units of DP-OPAA or 20 units of DP-OPH and 2-PAM (45 mg/kg) 
in a maximum volume of 10 µl/mg mouse, intravenously (dorsal tail vein injection) 
Sublethal doses of the OPs, DFP (3.5 mg/kg) or paraoxon (0.65 mg/kg), were injected 
subcutaneously. Blood was taken two min after OP injection, and centrifuged to separate the 
plasma. Cholinesterase activity was determined by the method of Ellman et al. (1961) as 
previously described for the standard assay, with the following modifications: 50 µl of 
plasma was diluted into 6.0 ml phosphate buffer (100 mM, pH 8.0). Two and a half 
milliliters of this plasma/buffer solution was substituted for the phosphate buffer in the 
standard assay. The reaction was blanked against 2.5 ml plasma/buffer and the absorbance 
recorded at 412 nm for 6 min. 
 
Results 
Formation of fluoride ions was directly proportional to the amount of DP-OPAA and the 
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formation of p-nitrophenol was directly proportional to the amount of DP-OPH, indicating 
that, under the conditions defined in this study, increases in amount of DP-OPAA (0.224 mM 
F- ion sec-1 µl-1 DP-OPAA) or DP-OPH (0.159 mM p-NP sec-1µl-1 DP-OPH) are equivalent 
to increases in amounts of enzyme present in the reaction mixture. The hydrolysis rates for 
both the DFP and paraoxon were linear over one minute for the concentration ranges of 
enzyme and substrate employed in these studies. The DP without enzyme did not hydrolyze 
DFP or paraoxon. It is important to note that in these studies the amount of encapsulated 
enzymes used was standardized, but not optimized.   
AChE inhibition was proportional to the concentration of DFP and paraoxon in the system 
(Fig. 1.), which indicates these compounds can effectively simulate an OP nerve agent.  In 
the presence of 18 mM DFP, cholinesterase was inhibited greater than 95%. When 2-PAM 
was employed with DFP, the cholinesterase activity was still inhibited up to 70%.  The 
application of DP-OPAA further reduced the DFP-mediated inhibition of cholinesterase to 
approximately 44% (Fig. 2.). Similar experiments with paraoxon showed that 0.7 
nMparaoxon inhibited 0.12 U of AChE greater than 98%.  The application of 2-PAM alone 
limited the inhibition to 90%, while the 2-PAM + DP-OPH combination decreased the 
inhibition to approximately 70% (Fig. 2.). Fig. 3A. shows the in vivo plasma cholinesterase 
activity in mice after administering sub-lethal doses of DFP alone, and in conjunction with 2-
PAM and 2-PAM + DP-OPAA/DP-OPH. Blood samples taken 2 min after DFP 
administration indicated that DFP inhibited the cholinesterase activity by approximately 
90%. This inhibition was significantly less when 2-PAM was employed alone, or in a 
combination with DP-OPAA. Similar effects on cholinesterase activity were observed when 
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paraoxon was employed with and without (DP-OPH) and/or 2-PAM (Fig. 3B.). 
Comparatively DP-OPH appeared to provide a better protection of cholinesterase activity 
than DP-OPAA.  
 
Discussion 
This study demonstrates the use of synthetic polymeric nanocapsules (DP) as an enzyme 
delivery system to antagonize the lethal effects of OP anticholinesterases. This relatively new 
concept combines recombinant enzyme biotechnology with recent developments in polymer 
chemistry to produce synthetic enzyme carriers. The present study was focused on the in vitro 
indication of DFP and paraoxon effects alone, in the presence of a reactivator, 2-PAM, 
and/or a DP-encapsulated OP-metabolizing enzyme, DP-OPAA or DP-OPH, by measuring 
the cholinesterase activity. Monitoring the cholinesterase activity in the biological system 
(Fig. 3.) was also used to identify OP exposure, as well as detoxification by the OP antidotes. 
(While acetylcholinesterase (3.1.1.7) can be determined from whole blood, when plasma is 
analyzed, we measure butyrylcholinesterase: (3.1.1.8) activity with acetylthiocholine as a 
substrate).  It has to be noted that oximes, such as 2-PAM, can react with acetylthiocholine 
(oximolysis), producing thiocholine what can react with the thiol reagent 5,5’-dithio-bis-2-
nitrobenzoic acid of the Ellman’s method (Guarisco et al., 2009; Kern et al., 2009; Sinko et 
al., 2007). This suggests that the Ellman method has to be employed critically in the presence 
of oximes: if the reaction of oximolysis is faster than the Ellman reaction under the 
experimental conditions, than the observed 5-thio-2-nitrobenzoic acid concentration can 
originate from both the cholinesterase reaction and the oximolysis of acetylthiocholine.   
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The antidotal regimen currently in use in the United States for the treatment of OP toxicity is 
the combination of 2-PAM and atropine. While this treatment can relieve the symptoms of 
OP toxicity, it does not remove the nerve agents from the body. Therefore, nerve agents may 
persist long after exposure, thus necessitating multiple applications of the 2-PAM + atropine 
regime. Presently, there are no antidotes approved for use that can eliminate OP agents from 
the body, although both OPAA and OPH have been shown to effectively decontaminate most 
of the OP agents and pesticides. This study demonstrates that the direct injection of 
appropriate amounts of enzyme can provide greater protection against the lethal effects of OP 
agents than the current treatment regimen of (2-PAM + Atropine). The magnitude and 
duration of this protection is found to be greatly increased if enzymes are entrapped into drug 
delivery biocarriers such as sterically stabilized liposomes (Petrikovics et al., 1999, 2000a, 
2000b), or carrier red blood cells (Cannon et al., 1992; Leung et al., 1986; Pei et al., 1994, 
1995; Petrikovics et al., 1995; Way et al., 1985).  Employing tree-like (dendritic) polymer 
based DP offers a number of advantages, including better water solubility, non-toxic nature, 
and most importantly, ease of encapsulation for delivery. The preparation of core shell highly 
branched polymers usually requires a multi-step synthesis. This poly(2-ethyloxazoline) based 
core shell DP was prepared by a one-pot polymerization process starting from commercially 
available monomers. The use of external enzymes as drug antidotes is a relative new concept 
in the history of drug antidotal therapy, and the present and previously reported results 
suggest that this approach has a great potential. These studies represent one of the biomedical 
applications of nanotechnology, the development of nano-structure delivery systems as 
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Figure 1.  AChE inhibition as a function of increasing amounts of (A) paraoxon and (B) 
DFP. The inhibition assays contained 0.5 mM acetylthiolcholine iodide, 33 nM 
DTNB, and 0.12 units of AChE in a final volume of 3 ml.  
 
Figure 2.  In vitro AChE activity in the presence of treatment combinations. The assay 
mixture contained 0.5 mM acetylcholine iodide, 33 mM DTNB, 0.12 U AChE, 
1.3 mM 2-PAM. Reactions represented in (A) all contained 18 nM DFP in all 
reactions, except the control, and 5 units of DP-OPAA as indicated.  The 
reactions represented in (B) all contained 0.7 nM paraoxon and 20 units of DP-
OPH where indicated.  In all cases, the control is uninhibited cholinesterase 
activity. 
 
Figure 3. In vivo plasma cholinesterase activity in mice.  Mice were pre-treated with 2-
PAM (45 mg/kg, iv.), or with 2-PAM + DP-enzyme combination. Blood samples 
were taken 2 min after subcutaneous injection of either 3.5 mg/kg DFP or 0.65 
mg/kg paraoxon.  A) DFP exposure.  DP-OPA was administered as 100 U i.v. B) 
Paraoxon exposure. One to two units of DP-OPH was administered as indicated. 
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Figure 3. 
 
 
